Primary Care PoC Diagnostics Market To Reach $22.09 Billion By 2030

Primary Care PoC Diagnostics Market Growth & Trends

The global primary care PoC diagnostics market size is expected to reach USD 22.09 billion by 2030, registering a 3.3% CAGR from 2025 to 2030, according to a new report by Grand View Research, Inc. Flexible and forward-thinking core molecular labs have been embracing and supporting the use of POC tests to move screening of many common targets to hospital receiving rooms and physicians’ offices.

As per a study conducted by the American Journal of Clinical Pathology in 2014, it was found that POC testing improved clinical operations for manufacturers by reducing follow-up calls and letters of patients by 85.0% and 89.0%, respectively, and reducing their follow-up visits by 61.0%. It was also observed that the number of tests ordered decreased by 21.0%.

Furthermore, rise in the number of tests receiving a waived status under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) is anticipated to aid market growth. Researchers and manufacturers are increasingly recommending these tests owing to cost reduction of about USD 12-15 per patient and reduction in follow up tests by about 50.0%. However, there is a massive overlap between different methods and their areas of usage. For instance, panels to measure glucose and quick international normalized ratio tests were originally meant for self-testing but are now used in hospitals and primary settings instead.

 Request a free sample copy or view report summary: Primary Care PoC Diagnostics Market Report

Primary Care PoC Diagnostics Market Report Highlights

• The cancer markers segment is expected to register the fastest CAGR of 5.3% over the forecast period. The rising cancer incidences, increased demand for screening cancer, and technological advancements are driving the segment’s growth.

• The pharmacy & retail clinics segment led the market with a revenue share of 47.3% in 2024. The increasing coverage of health plans has reduced healthcare costs and improved access to care, enabling pharmacies and retail clinics to offer PoC testing.

• The North America primary care POC diagnostics market is more developed compared to the rest of the world. The regional segment is fueled by availability of several innovative and advanced POC diagnostic products and growing awareness and demand for point-of-care diagnostics in primary home healthcare and assisted healthcare

• The U.S. market is witnessing a shift toward increasing patient involvement in home care, home-based tests, and monitoring instruments. In addition, digitalization, EHR, telemedicine, and web-enabled solutions of monitoring data are gaining pace in U.S., thereby driving its growth

Primary Care PoC Diagnostics Market Segmentation

Grand View Research has segmented the global primary care PoC diagnostics market based on disease, end use, and region:

Primary Care PoC Diagnostics Disease Outlook (Revenue, USD Million, 2018 - 2030)

• Glucose Testing

• Hb1Ac Testing

• Coagulation Testing

• Fertility/Pregnancy

• Infectious Disease

• Cardiac Markers

• Thyroid Stimulating Hormone

• Hematology

• Primary Care Systems

• Decentralized Clinical Chemistry

• Feces

• Lipid Testing

• Cancer Marker

• Blood Gas/Electrolytes

• Ambulatory Chemistry

• Drug of Abuse (DOA) Testing

• Autoimmune Diseases

• Urinalysis/Nephrology

Primary Care PoC Diagnostics End Use Outlook (Revenue, USD Million, 2018 - 2030)

• Pharmacy & Retail Clinics

• Physician Office

• Urgent Care Clinics

• Non-practice Clinics

Primary Care PoC Diagnostics Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in Primary Care PoC Diagnostics Market

• F Hoffmann-La Roche Ltd.

• Danaher

• Abbott

• Siemens Healthineers

• BIOMÉRIEUX

• QIAGEN

• Nova Biomedical

• Johnson & Johnson Services, Inc.

• OraSure Technologies, Inc.

• BD